{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:56:48Z","timestamp":1792652208766,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13142-9","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T21:49:38Z","timestamp":1747086578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics"],"prefix":"10.1007","volume":"272","author":[{"given":"Michael","family":"Rosenbloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schnee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saanvi","family":"Nimma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gzesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"1","key":"13142_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"issue":"6","key":"13142_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"7","key":"13142_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40263-024-01097-w","volume":"38","author":"MH Rosenbloom","year":"2024","unstructured":"Rosenbloom MH, O\u2019Donohue T, Zhou-Clark D et al (2024) A framework for the administration of anti-amyloid monoclonal antibody treatments in early-stage Alzheimer\u2019s disease. CNS Drugs 38(7):493\u2013505","journal-title":"CNS Drugs"},{"issue":"3","key":"13142_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD et al (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10(3):362\u2013377","journal-title":"J Prev Alzheimers Dis"},{"key":"13142_CR5","unstructured":"https:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-clinical-data-demonstrates-three-years-continuous-treatment. Accessed."},{"issue":"1","key":"13142_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13195-024-01640-3","volume":"16","author":"S Ji","year":"2024","unstructured":"Ji S, Rosenbloom M (2024) Intracerebral hemorrhage following mild ARIA-H in an APOE epsilon2 carrier receiving lecanemab. Alzheimers Res Ther 16(1):265","journal-title":"Alzheimers Res Ther"},{"key":"13142_CR7","first-page":"9343514","volume":"2022","author":"SA Beshir","year":"2022","unstructured":"Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB (2022) Aducanumab therapy to treat Alzheimer\u2019s disease: a narrative review. Int J Alzheimers Dis 2022:9343514","journal-title":"Int J Alzheimers Dis"},{"issue":"8","key":"13142_CR8","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","volume":"30","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews SJ, Beach TG et al (2024) Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease. Nat Med 30(8):2121\u20132124","journal-title":"Nat Med"},{"issue":"3","key":"13142_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/jgs.18124","volume":"71","author":"JS Fasnacht","year":"2023","unstructured":"Fasnacht JS, Wueest AS, Berres M et al (2023) Conversion between the montreal cognitive assessment and the mini-mental status examination. J Am Geriatr Soc 71(3):869\u2013879","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"13142_CR10","first-page":"1078","volume":"29","author":"AC Wright","year":"2023","unstructured":"Wright AC, Lin GA, Whittington MD et al (2023) The effectiveness and value of lecanemab for early Alzheimer disease: a summary from the institute for clinical and economic review\u2019s California technology assessment forum. J Manag Care Spec Pharm 29(9):1078\u20131083","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13142-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:25Z","timestamp":1749907525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13142-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13142"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13142-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR has been paid by Eisai for consulting and serving on an advisory board. DW has been paid by Eisai for consulting and serving on an advisory board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"NA (evaluation of clinical initiative).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"394"}}